Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 4/20 | 0.50 |
| ▸ | SDCBP | O00560 | 4/20 | 0.50 |
| ▸ | SDC2 | P34741 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184728 | 1.00 | ALOX15 (0.63) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL6187371 | 1.00 | ALOX15 (0.63) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL1097927 | 1.00 | ALOX15 (0.63) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL6186957 | 1.00 | ALOX15 (0.63) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL13584056 | 0.99 | ALOX15 (0.64) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL6187235 | 0.99 | ALOX15 (0.64) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL13585171 | 0.94 | ALOX15 (0.67) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL13585168 | 0.94 | ALOX15 (0.67) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL2669076 | 0.89 | ALOX15 (0.52) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL1107311 | 0.88 | ALOX15 (0.51) | ALOX15MAPTSMN1; SMN2KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697705-B2 | Isoindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2059522-B1 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| CN-103502242-A | Isoindolinone derivatives | HOFFMANN LA ROCHE | 2014-01-08 | — | — | CN | disclosed |
| US-8614332-B2 | Substituted pyrazolylamides useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130296339-A1 | ISOINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2013-11-07 | — | — | US | disclosed |
| US-8470866-B2 | Isoindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120283271-A1 | ISOINDOLINONE DERIVATIVES | BERTHEL STEVEN JOSEPH (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| EP-1349856-B1 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| EP-1349856-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6482951-B2 | ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GUERTIN KEVIN RICHARD (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002048106-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GCKR, GCK, PGK2 | ALOX15 3998/4885MAPT 3865/4885SMN1; SMN2 4406/4885 |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | ALOX15 3476/4885MAPT 4710/4885SMN1; SMN2 4603/4885 |
| US-20120283271-A1 | ISOINDOLINONE DERIVATIVES | GCK, GCKR, PDK2 | ALOX15 1580/4885MAPT 3408/4885SMN1; SMN2 3036/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | ALOX15 3777/4885MAPT 4511/4885SMN1; SMN2 4710/4885 |
| US-20130296339-A1 | ISOINDOLINONE DERIVATIVES | GCK, GCKR, PDK2 | ALOX15 1580/4885MAPT 3408/4885SMN1; SMN2 3036/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | ALOX15 3967/4885MAPT 4446/4885SMN1; SMN2 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.